Altasciences Partners with Evidence Matters to Deploy AI-Enhanced Regulatory Writing Technology
核心洞察
Altasciences (搜索), a fully integrated CRO/CDMO, has announced a strategic collaboration with Evidence Matters (搜索) to advance AI-enhanced text engineering for regulatory writing in life sciences.
The partnership combines Altasciences (搜索)' real-world drug development expertise with Evidence Matters (搜索)' patent-pending Text Engineering technology, which delivers near-deterministic accuracy in regulatory documentation.
Evidence Matters (搜索)' RegulatoryFlow (搜索) platform demonstrated elimination of table transfer errors affecting one-third of regulatory documents and reduced TFL-to-Word processing time by more than 50%.
Altasciences (搜索), a fully integrated contract research organization and contract development and manufacturing organization (CRO/CDMO), has announced a strategic collaboration with Evidence Matters (搜索) to advance artificial intelligence-enhanced text engineering for regulatory writing in life sciences. The partnership aims to transform the quality, consistency, and speed of regulatory documentation through innovative AI technology.
Revolutionary Text Engineering Technology
The collaboration centers on Evidence Matters (搜索)' patent-pending Text Engineering technology, which delivers near-deterministic accuracy in regulatory writing by reducing variability and improving documentation standards. The company's RegulatoryFlow (搜索) platform ("RegFlow") and specialized services unify clinical data and documents, simplify workflows, and accelerate the work of key life sciences professionals, from medical writers to regulatory specialists.
"With Text Engineering, we're moving beyond automation into a new era of precision and consistency," said Dr. Ofer Avital, Founder and Director of Evidence Matters (搜索). "The impact on regulatory documentation, from timelines to accuracy, is transformative."
Demonstrated Performance Improvements
In testing against manual work, RegulatoryFlow (搜索) demonstrated significant performance enhancements. The platform eliminated table transfer errors that can affect approximately one-third of tables in life science regulatory documents, while reducing TFL-to-Word processing time by more than 50%. These improvements address critical pain points in regulatory documentation workflows that have traditionally been time-consuming and error-prone.
Seamless Integration and Rapid Deployment
Unlike traditional enterprise platforms that require extensive implementation timelines, RegulatoryFlow (搜索) integrates seamlessly with existing Microsoft Word workflows. This compatibility enables rapid deployment in weeks rather than months and meets medical writers right where they work, minimizing disruption to established processes.
Strategic Partnership Approach
Altasciences (搜索) is deeply engaged in the partnership, contributing real-world training data and conducting user testing to ensure the technology meets the needs of frontline teams. This hands-on approach reflects the company's commitment to leveraging artificial intelligence to drive innovation, streamline complex processes, and deliver better outcomes for both sponsors and patients.
"We are excited to work alongside Evidence Matters (搜索) to co-develop technology that directly enhances the quality and efficiency of regulatory writing," said Nicole Maciolek, Vice President, Research Services at Altasciences (搜索). "Through this partnership, we're not just implementing AI, we're actively shaping its future as an indispensable tool in life sciences."
Industry Impact
The collaboration represents a significant step forward in clinical trial implementation and documentation, helping sponsors move faster and with greater confidence from candidate selection to clinical proof of concept and beyond. By combining Altasciences (搜索)' 30-year track record in drug development with Evidence Matters (搜索)' 25 years of domain expertise in clinical trials data science, the partnership aims to redefine what's possible in regulatory documentation.
Evidence Matters (搜索) has expanded its expertise across multiple industries, empowering organizations to transform complex data into actionable insights. The company is guided by a seasoned team of data scientists and industry leaders who drive innovation and shape the future of data-driven decision-making in life sciences.